Table A1.
Baseline health characteristics for each group at patient level.
| Characteristic | Usual care | Eligible patients (ITT) | Patients with counseling (PP) | Overall |
|---|---|---|---|---|
| USE OF MEDICATION PRECEDING INDEX DATE: | ||||
| Patients starting with RAS-inhibitor | n = 1317 | n = 850 | n = 257 | n = 2167 |
| Antidiabetics (A10) | 176 (13.3) | 96 (11.2) | 36 (14.0) | 272 (12.6) |
| Antithrombotics (B01) | 295 (22.3) | 227 (26.7) | 67 (26.1) | 522 (24.1) |
| Antihypertensives | 604 (46.8) | 438 (52.5) | 134 (53.0) | 1042 (49.1) |
| Patients starting with statin | n = 1345 | n = 839 | n = 268 | n = 2184 |
| Antidiabetics (A10) | 246 (18.3) | 128 (15.3) | 34 (12.7) | 374 (17.1) |
| Antithrombotics (B01) | 425 (31.6) | 279 (33.3) | 79 (29.5) | 704 (32.2) |
| Antihypertensives | 526 (39.3) | 369 (44.5) | 126 (47.5) | 895 (41.3) |
| Visit to cardiologist or internist in 12 months before index | 465 (34.6) | 280 (33.3) | 90 (33.6) | 745 (34.1) |
| Patients starting with bisphosphonate | n = 252 | n = 319 | n = 137 | n = 571 |
| Calcium suppletion (A12A) | 123 (48.8) | 163 (51.1) | 68 (49.6) | 286 (50.1) |
| Predniso(lo)ne (H02AB06 or H02AB07) | 68 (27.0) | 85 (26.6) | 38 (27.7) | 153 (26.8) |
| Vitamin D (A11CC05) | 115 (45.6) | 155 (48.6) | 67 (48.9) | 270 (47.3) |
| Visit to internist in 12 months before index | 248 (98.4) | 298 (93.4) | 132 (96.4) | 546 (95.6) |
| Patients starting with antidepressant | n = 723 | n = 1086 | n = 392 | n = 1809 |
| Antipsychotic (N05) | 47 (6.5) | 53 (4.9) | 12 (3.1) | 100 (5.5) |
| Benzodiazepin (N05BA, N05CD or N05CF) | 250 (34.6) | 307 (28.3) | 109 (27.9) | 557 (30.8) |
| Visit to psychiatrist in 12 months before index | 141 (19.5) | 276 (25.4) | 99 (25.3) | 417 (23.1) |
Values are number (percentages) unless stated otherwise.
Antihypertensives: Antihypertensives (C02) + Diuretics (C03) + Beta blocking agents (BBA, C07) + Calcium channel blockers (CCB, C08) + RAS inhibitors (C09)).